Bioenergetics shapes cellular death pathways in Leber's hereditary optic neuropathy: a model of mitochondrial neurodegeneration
- PMID: 15282189
- DOI: 10.1016/j.bbabio.2004.05.009
Bioenergetics shapes cellular death pathways in Leber's hereditary optic neuropathy: a model of mitochondrial neurodegeneration
Abstract
Leber's hereditary optic neuropathy (LHON) was the first maternally inherited disease to be associated with point mutations in mitochondrial DNA and is now considered the most prevalent mitochondrial disorder. The pathology is characterized by selective loss of ganglion cells in the retina leading to central vision loss and optic atrophy, prevalently in young males. The pathogenic mtDNA point mutations for LHON affect complex I with the double effect of lowering the ATP synthesis driven by complex I substrates and increasing oxidative stress chronically. In this review, we first consider the biochemical changes associated with the proton-translocating NADH-quinone oxidoreductase of mitochondria in cybrid cells carrying the most common LHON mutations. However, the LHON cybrid bioenergetic dysfunction is essentially compensated under normal conditions, i.e. in glucose medium, but is unrevealed by stressful conditions such as growing cybrids in glucose free/galactose medium, which forces cells to rely only on respiratory chain for ATP synthesis. In fact, the second part of this review deals with the investigation of LHON cybrid death pathway in galactose medium. The parallel marked changes in antioxidant enzymes, during the time-course of galactose experiments, also reveal a relevant role played by oxidative stress. The LHON cybrid model sheds light on the complex interplay amongst the different levels of biochemical consequences deriving from complex I mutations in determining neurodegeneration in LHON, and suggests an unsuspected role of bioenergetics in shaping cell death pathways.
Similar articles
-
Severe impairment of complex I-driven adenosine triphosphate synthesis in leber hereditary optic neuropathy cybrids.Arch Neurol. 2005 May;62(5):730-6. doi: 10.1001/archneur.62.5.730. Arch Neurol. 2005. PMID: 15883259
-
Leber's hereditary optic neuropathy (LHON) pathogenic mutations induce mitochondrial-dependent apoptotic death in transmitochondrial cells incubated with galactose medium.J Biol Chem. 2003 Feb 7;278(6):4145-50. doi: 10.1074/jbc.M210285200. Epub 2002 Nov 21. J Biol Chem. 2003. PMID: 12446713
-
Apoptotic cell death of cybrid cells bearing Leber's hereditary optic neuropathy mutations is caspase independent.Ann N Y Acad Sci. 2003 Dec;1010:213-7. doi: 10.1196/annals.1299.037. Ann N Y Acad Sci. 2003. PMID: 15033723
-
Leber's Hereditary Optic Neuropathy as a Promising Disease for Gene Therapy Development.Adv Ther. 2019 Dec;36(12):3299-3307. doi: 10.1007/s12325-019-01113-2. Epub 2019 Oct 11. Adv Ther. 2019. PMID: 31605306 Free PMC article.
-
[Past, present, and future in Leber's hereditary optic neuropathy].Nippon Ganka Gakkai Zasshi. 2001 Dec;105(12):809-27. Nippon Ganka Gakkai Zasshi. 2001. PMID: 11802455 Review. Japanese.
Cited by
-
Visual function in chronic Leber's hereditary optic neuropathy during idebenone treatment initiated 5 to 50 years after onset.Graefes Arch Clin Exp Ophthalmol. 2019 Dec;257(12):2751-2757. doi: 10.1007/s00417-019-04444-6. Epub 2019 Sep 3. Graefes Arch Clin Exp Ophthalmol. 2019. PMID: 31482278
-
Pathogenesis and treatment of mitochondrial disorders.Adv Exp Med Biol. 2009;652:139-70. doi: 10.1007/978-90-481-2813-6_10. Adv Exp Med Biol. 2009. PMID: 20225024 Free PMC article. Review.
-
Eye Opener in Stroke.Stroke. 2019 Aug;50(8):2197-2206. doi: 10.1161/STROKEAHA.119.025249. Epub 2019 Jun 27. Stroke. 2019. PMID: 31242827 Free PMC article.
-
Electrophysiological and Structural Changes in Chinese Patients with LHON.J Ophthalmol. 2020 Mar 30;2020:4734276. doi: 10.1155/2020/4734276. eCollection 2020. J Ophthalmol. 2020. PMID: 32318281 Free PMC article.
-
Increase in Mitochondrial Biogenesis in Neuronal Cells by RNS60, a Physically-Modified Saline, via Phosphatidylinositol 3-Kinase-Mediated Upregulation of PGC1α.J Neuroimmune Pharmacol. 2018 Jun;13(2):143-162. doi: 10.1007/s11481-017-9771-4. Epub 2017 Nov 29. J Neuroimmune Pharmacol. 2018. PMID: 29188424 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources